Why Billion‑Dollar “Seed” Rounds Don’t Rewrite Venture Math

Headlines about billion‑dollar seed financings in AI suggest the early-stage game has been fundamentally redesigned. New companies are announcing first checks in the hundreds of millions or even billions of dollars. It’s tempting to read that and assume that, from now on, meaningful AI businesses must start life with war chests that look more like late-stage growth rounds.

A closer look at the numbers, and at another sector that has lived with mega first rounds for years, tells a much more sober story. Large “seed” rounds are real, but they are not representative of what gets funded, nor of what reliably produces venture‑scale returns for the earliest investors.

To understand why, it helps to look at biotech, an industry that has long required heavy capital up front. Investors at Bison Ventures have spent years in that market and have watched nine‑figure first financings play out across drug development, tools and therapeutics companies. In biotech, raising $100 million or more on day one isn’t unusual; Phase 1 clinical trials and core lab infrastructure simply don’t fit inside a $3 million seed budget.

That scientific reality, however, has not translated into an equally outsized payoff pattern for the earliest equity. Bison assembled a dataset of roughly 200 companies over the past 15 years that publicly disclosed first rounds of $100 million or higher. Only about one in five has reached an exit of any kind. Narrow that further to outcomes where the initial investors earned truly venture‑style returns – roughly 10x their money or more – and you are looking at only a small subset of that already modest group.

Put another way, on the order of 1% of companies that launched with nine‑figure first financings ultimately produced returns that fully justify early‑stage risk capital. That’s a strikingly low hit rate for a cohort that, on paper, had both ample capital and significant technical ambition. In many of these cases, the very feature that made the funding newsworthy – capital intensity and high entry valuation – worked against the return profile.

AI’s current funding environment looks similar on the surface: staggering checks written into brand‑new entities, often before there is a shipped product or revenue. There are standout examples at the model layer and in infrastructure where first rounds have climbed to several hundred million dollars or far beyond. Yet even the biggest winners in this wave do not obviously overturn the historical math for first‑check investors.

When marquee AI platforms eventually list publicly or transact, early participants are widely expected to see 30x to 40x multiples on their initial stakes at projected valuations. Those are excellent results by any conventional standard. But compared with earlier generations of breakout technology companies, they look compressed. Early backers of companies such as Google and Uber saw multiples in the hundreds or even thousands of times their original checks, with just tens of millions – or far less – invested at inception.

The difference is not that today’s AI companies are inherently weaker or less transformative than past giants. The core distinction is the price of entry. Classic early‑stage wins were written at valuations that left enormous room for compounding as the business scaled. When a company starts life already valued in the billions, a very large portion of the eventual upside has been baked into that first price.

Meanwhile, away from the splashy headlines, most AI and software startups are still raising what would traditionally be recognized as seeds: single‑digit or low double‑digit millions for the first institutional round. Those quieter financings also appear in the current crop of AI success stories. Several well‑known AI application and model companies began with early checks ranging from roughly $2 million to $25 million, and in one case under $10 million, before going on to reach valuations north of $5 billion with substantial revenue traction.

For founders, that pattern matters. It demonstrates that you don’t need a multi‑hundred‑million‑dollar “seed” to build a generational AI business. In fact, many of the most impressive up‑and‑to‑the‑right stories in the sector have come from teams that raised comparatively modest first rounds, proved product‑market fit, and let valuation expand as evidence accumulated. The colossal outliers exist, but they are not the blueprint.

From an investor’s perspective, the lesson is equally clear. Very large first checks into capital‑hungry businesses can occasionally work – biotech and AI both have examples – but across a sufficiently large sample, the odds of a mega‑seed producing a 10x‑plus multiple have been low. Building a portfolio that assumes most of those gigantic early rounds will be home runs runs counter to 15 years of data in sectors where that pattern has already been tested.

For founders weighing how much to raise and at what price, this backdrop is a reminder that capital intensity alone does not confer defensibility. Access to GPUs, lab space or specialized infrastructure may require substantial spend, but piling on extra capital at a very high initial valuation does not, in itself, create a competitive moat. It simply raises the bar for what future rounds and eventual exits must deliver to keep earlier stakeholders whole.

What has worked repeatedly across technology cycles is more prosaic: raise enough to reach clear milestones, protect meaningful ownership for both founders and early backers, and price the round so there is room for value to compound over time. That approach will never generate the most dramatic funding announcement, but historically it has been more closely associated with the true outlier returns that define venture as an asset class.

Looking ahead, it is reasonable to expect a handful of today’s mega‑funded AI companies to deliver strong exits. When they do, they will improve the statistics for the nine‑figure‑seed cohort and may even double the tiny pool of true outlier returns in the dataset Bison examined. Yet the broader pattern is unlikely to flip overnight. For most founders, the path to building a significant company in AI or biotech will still run through disciplined capital planning and staged validation, not through chasing the biggest possible first check.